Jerini AG was a pharmaceutical company based in Berlin, Germany, which focused on the discovery and development of novel peptide-based drugs. Using a proprietary technology platform, Peptides-to-Drugs (P2D), Jerini pursued disease indications for which limited, inadequate, or no treatment options exist. As a result, Jerini established a drug pipeline composed of its own programs as well as others in collaboration with partners. Jerini's commercialization strategy was to market new drugs in niche indications independently and in larger indications with partners. Jerini was acquired by Shire plc in 2008.

Property Value
dbo:abstract
  • Die Jerini AG war ein Pharmaunternehmen, das auf peptidbasierte Arzneimittel spezialisiert war. Mithilfe einer Technologieplattform „Peptides-to-Drugs“ (P2D) wurde an Wirkstoffen für Medikamente in den Indikationsbereichen Augenheilkunde, Onkologie und Entzündungserkrankungen geforscht. Neben der Entwicklung eigener Wirkstoffe unterhielt das Unternehmen Kooperationen mit anderen Unternehmen. 2008 wurde Jerini vom britischen Unternehmen Shire plc übernommen. (de)
  • L’entreprise pharmaceutique berlinoise Jerini AG est spécialisée dans la recherche, le développement et la commercialisation de médicaments innovants, de nature peptidique. Sa plate-forme technologique « Peptides-to-Drugs » (P2D) lui permet de développer des médicaments pour des maladies pour lesquelles il n’existait jusqu’à présent aucune possibilité de traitement, ou seulement des possibilités de traitement réduites. En plus du développement de ses propres substances actives, l’entreprise collabore avec d’autres sociétés. L’entreprise prévoit de commercialiser elle-même ses médicaments pour des indications de niche, et dans les domaines d’indication plus vastes, d’assurer la commercialisation en coopération avec des partenaires. (fr)
  • Jerini AG è un'azienda farmaceutica con sede a Berlino la cui attività principale è basata sulla scoperta, lo sviluppo e la commercializzazione di nuovi farmaci peptidici. La società opera nel settore delle malattie rare per le quali non esistono trattamenti o per le quali le opzioni terapeutiche sono limitate, settore nel quale ha sviluppato in proprio e in collaborazione con partner una pipeline di prodotti. Firazyr, il principale farmaco della società, è stato sviluppato per il trattamento dell'angioedema ereditario e sarà commercializzato in Europa a partire dal terzo trimestre 2008. Jerini ha inoltre dato avvio ad altri programmi di sviluppo in diverse aree terapeutiche ed in particolare in oftalmologia, oncologia e nel campo delle infiammazioni. Il 3 luglio 2008 Jerini e Shire Limited hanno annunciato una partnership strategica che prevede l'acquisizione di Jerini da parte di Shire al prezzo di Euro 6,25 per azione. Il management prevede che l'acquisizione sarà completata entro l'autunno 2008. (it)
  • Jerini AG was a pharmaceutical company based in Berlin, Germany, which focused on the discovery and development of novel peptide-based drugs. Using a proprietary technology platform, Peptides-to-Drugs (P2D), Jerini pursued disease indications for which limited, inadequate, or no treatment options exist. As a result, Jerini established a drug pipeline composed of its own programs as well as others in collaboration with partners. Jerini's commercialization strategy was to market new drugs in niche indications independently and in larger indications with partners. Jerini was acquired by Shire plc in 2008. Jerini started operations in 1994. Jerini's subsidiaries Jerini US Inc. and JPT Peptide Technologies GmbH, provider of peptides and peptide microarrays, were acquired by Theracode GmbH, Mainz in 2009. Jerini was financed with venture capital provided by TVM and HealthCap. It went public on the Prime Standard of the Frankfurt Stock Exchange (JI4), and had raised a total of over 130 million Euro in public and private financing to date. (en)
dbo:foundationPlace
dbo:foundingYear
  • 1994-01-01 (xsd:date)
dbo:location
dbo:numberOfEmployees
  • 139 (xsd:integer)
dbo:product
dbo:thumbnail
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 6588551 (xsd:integer)
dbo:wikiPageRevisionID
  • 728833624 (xsd:integer)
dbp:keyPeople
  • Adi Hoess, Chief Commercial Officer
  • Berndt Modig, Chief Financial Officer
  • Jens Schneider-Mergener, CEO
  • Jochen Knolle, Chief Scientific Officer, Head of R & D
dbp:logo
dct:subject
http://purl.org/linguistics/gold/hypernym
rdf:type
rdfs:comment
  • Die Jerini AG war ein Pharmaunternehmen, das auf peptidbasierte Arzneimittel spezialisiert war. Mithilfe einer Technologieplattform „Peptides-to-Drugs“ (P2D) wurde an Wirkstoffen für Medikamente in den Indikationsbereichen Augenheilkunde, Onkologie und Entzündungserkrankungen geforscht. Neben der Entwicklung eigener Wirkstoffe unterhielt das Unternehmen Kooperationen mit anderen Unternehmen. 2008 wurde Jerini vom britischen Unternehmen Shire plc übernommen. (de)
  • L’entreprise pharmaceutique berlinoise Jerini AG est spécialisée dans la recherche, le développement et la commercialisation de médicaments innovants, de nature peptidique. Sa plate-forme technologique « Peptides-to-Drugs » (P2D) lui permet de développer des médicaments pour des maladies pour lesquelles il n’existait jusqu’à présent aucune possibilité de traitement, ou seulement des possibilités de traitement réduites. En plus du développement de ses propres substances actives, l’entreprise collabore avec d’autres sociétés. L’entreprise prévoit de commercialiser elle-même ses médicaments pour des indications de niche, et dans les domaines d’indication plus vastes, d’assurer la commercialisation en coopération avec des partenaires. (fr)
  • Jerini AG was a pharmaceutical company based in Berlin, Germany, which focused on the discovery and development of novel peptide-based drugs. Using a proprietary technology platform, Peptides-to-Drugs (P2D), Jerini pursued disease indications for which limited, inadequate, or no treatment options exist. As a result, Jerini established a drug pipeline composed of its own programs as well as others in collaboration with partners. Jerini's commercialization strategy was to market new drugs in niche indications independently and in larger indications with partners. Jerini was acquired by Shire plc in 2008. (en)
  • Jerini AG è un'azienda farmaceutica con sede a Berlino la cui attività principale è basata sulla scoperta, lo sviluppo e la commercializzazione di nuovi farmaci peptidici. La società opera nel settore delle malattie rare per le quali non esistono trattamenti o per le quali le opzioni terapeutiche sono limitate, settore nel quale ha sviluppato in proprio e in collaborazione con partner una pipeline di prodotti. Firazyr, il principale farmaco della società, è stato sviluppato per il trattamento dell'angioedema ereditario e sarà commercializzato in Europa a partire dal terzo trimestre 2008. Jerini ha inoltre dato avvio ad altri programmi di sviluppo in diverse aree terapeutiche ed in particolare in oftalmologia, oncologia e nel campo delle infiammazioni. Il 3 luglio 2008 Jerini e Shire Limite (it)
rdfs:label
  • Jerini (de)
  • Jerini (en)
  • Jerini (fr)
  • Jerini (it)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:homepage
foaf:isPrimaryTopicOf
foaf:name
  • Jerini AG (en)
is dbo:wikiPageRedirects of
is foaf:primaryTopic of